Pitocin
Evidence Grade A — Regulatory approved. 28829 published studies. 811 registered clinical trials.
Loading...
Oxytocin (sold as Pitocin) is a synthetic version of the naturally occurring "love hormone" — produced in the brain and involved in childbirth, breastfeeding, and social bonding. In hospitals, it is one of the most commonly used medications in obstetrics: given intravenously to induce or strengthen labour contractions and to prevent dangerous bleeding after delivery. It is on the WHO's List of Essential Medicines.
28,829 published studies: 13927 human, 11544 animal, 2044 in-vitro, 3907 reviews
Oxytocin (as Pitocin) is used worldwide for labour induction, labour augmentation, and prevention of postpartum haemorrhage. It requires careful intravenous dose titration because excessive stimulation can cause dangerously strong contractions.
Beyond obstetrics, oxytocin has been the subject of extensive research into its behavioural and psychological effects, including studies in autism spectrum disorder, anxiety, post-traumatic stress disorder, and social cognition. However, intranasal oxytocin for behavioural applications remains experimental, and results from clinical trials have been mixed. The WHO lists injectable oxytocin as an essential medicine, and its availability and proper storage (requiring refrigeration) are significant public health concerns in low-resource settings.
Oxytocin targets specific receptors on the smooth muscle of the uterus, triggering powerful rhythmic contractions. During pregnancy, the number of these receptors increases dramatically (up to 300-fold by term), which is why the uterus becomes increasingly sensitive to oxytocin as pregnancy progresses. Oxytocin also acts on muscle cells in the breast to trigger the 'let-down' reflex during breastfeeding. Beyond these reproductive roles, oxytocin acts in the brain to influence social bonding, trust, and emotional responses, earning it the popular label of the 'love hormone.'
Oxytocin's role in obstetric practice is well established with decades of clinical experience. The WHO recommends it as the preferred drug for preventing postpartum haemorrhage — the leading cause of maternal death worldwide. Safe use requires careful dose titration because excessive stimulation can cause dangerously strong contractions. Beyond obstetrics, there has been extensive research into intranasal oxytocin for behavioural and neuropsychiatric conditions — autism, social anxiety, PTSD, and trust-related disorders. Results have been largely disappointing: a major 2021 trial for autism was negative, and meta-analyses show no consistent benefit. Safety concerns with high doses include water retention and dangerously low sodium levels (due to structural similarity to vasopressin). Proper storage requiring refrigeration remains a significant public health challenge in low-resource settings where postpartum haemorrhage is most common.
Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)
Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali
3-hour Versus 12-hour Double-balloon Catheter for Labor Induction
Reducing Self-Dehumanization to Examine Oxytocin and Suicide Risk
Emotions From Salivary Biomarkers in an Architectural Context
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 7
FDA SUPPL 9
FDA SUPPL 8
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 1
FDA SUPPL 13
FDA SUPPL 14
FDA SUPPL 2
FDA SUPPL 16
FDA SUPPL 15
FDA SUPPL 3
FDA SUPPL 17
FDA SUPPL 4
FDA SUPPL 18
FDA SUPPL 5
FDA SUPPL 8
FDA SUPPL 6
FDA SUPPL 7
FDA SUPPL 23
FDA SUPPL 20
FDA SUPPL 22
FDA SUPPL 9
Health Canada Market Authorisation
FDA SUPPL 12
FDA SUPPL 11
FDA SUPPL 24
FDA SUPPL 19
FDA SUPPL 13
FDA SUPPL 26
FDA SUPPL 25
FDA SUPPL 14
FDA SUPPL 15
FDA SUPPL 16
FDA SUPPL 27
FDA SUPPL 28
FDA SUPPL 17
FDA SUPPL 20
FDA SUPPL 19
FDA SUPPL 18
FDA SUPPL 22
FDA SUPPL 21
FDA SUPPL 23
FDA SUPPL 28
FDA SUPPL 34
FDA ORIG 1
FDA SUPPL 32
FDA SUPPL 42
FDA SUPPL 31
FDA SUPPL 33
FDA SUPPL 41
FDA SUPPL 49
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
